Description:
TAY-SACHS DISEASE; TSD
HEXOSAMINIDASE A; HEXA
Repository
|
NIGMS Human Genetic Cell Repository
|
Subcollection |
Heritable Diseases Lysosomal Storage Diseases |
Class |
Disorders of Lipid Metabolism |
Cell Type
|
Fibroblast
|
Transformant
|
Untransformed
|
Race
|
White
|
Ethnicity
|
JEWISH
|
Family Member
|
1
|
Relation to Proband
|
proband
|
Confirmation
|
Clinical summary/Case history
|
Species
|
Homo sapiens
|
Common Name
|
Human
|
Remarks
|
|
Passage Frozen |
8 |
|
IDENTIFICATION OF SPECIES OF ORIGIN |
Species of Origin Confirmed by Nucleoside Phosphorylase, Glucose-6-Phosphate Dehydrogenase, and Lactate Dehydrogenase Isoenzyme Electrophoresis |
|
MUTATION VERIFICATION |
Ohno and Suzuki (Biochem Biophys Res Comm 153:463 1988) reported that this patient had 2 normal alpha-chain alleles with respect to the splice junction mutation observed for 2 other Ashkenazi Jewish TaySachs disease patients. Myerowitz and Hogikyan (SCIENCE 232:1646-1648 1986) observed that on the basis of DNA hybridization analyses using a cDNA coding for the alpha chain of human B-hexosaminidase the alpha chain gene for this Ashkenazi Tay-Sachs patient appears intact while the alpha chain gene of French-Canadian patients has a 5 prime deletion of approximately 5 to 8 kilobases. Arpaia et al (NATURE 333:85-86 1988) identified the presence of a single base mutation in the genomic DNA of this Tay-Sachs disease patient by finding a DdeI restriction site resulting from the substitution of a C for a G in the first nucleotide of intron 12. This mutation was present in a single dose and results in defective splicing of mRNA. Confirming the results reported by Ohno and Suzuki (1988) Myerowitz (Proc Natl Acad Sci USA 85:3955-3959 1988) reported that this cell culture lacked the splice junction mutation for either alpha chain allele. Myerowitz et al (J Biol Chem 263:18587-89 1988) performed sequence analysis of the alpha chain gene promoter region exon and splice junctions regions and polyadenylation signal area which revealed that this patient had a 4 base pair insertion in exon 11. This mutation introduces a premature termination signal in exon 11 which results in a deficiency of mRNA. Only one alpha chain allele of this patient bears the insertion. This lesion was found in approximately 70% of TaySachs carriers in the Ashkenazi Jewish population. Paw et al (Proc Natl Acad Sci USA 86:2413-2417 1989) reported that these fibroblasts from an infantile Tay-Sachs disease patient lacked the serine for glycine substitution at position 269 of the alpha-subunit of B-hexosaminidase which was observed for adult-onset and chronic GM2 gangliosidosis patients of Ashkenazi Jewish origin. |
|
beta-N-acetylhexosaminidase (hexosaminidase A) |
According to the submitter, biochemical test results for this subject showed decreased enzyme activity. EC Number: 3.2.1.52 |
|
Gene |
HEXA |
Chromosomal Location |
15q23-q24 |
Allelic Variant 1 |
606869.0001; TAY-SACHS DISEASE |
Identified Mutation |
c.1274_1277dupTATC; Myerowitz and Costigan [J Biol Chem 263: 18587 (1988)] demonstrated that the most frequent DNA lesion in Tay-Sachs disease of Ashkenazi Jews is a 4-bp insertion in exon 11. This mutation introduces a premature termination signal in exon 11, resulting in a deficiency of mRNA. This is the most frequent defect underlying Tay-Sachs disease in the Ashkenazi Jewish population. This mutation is alternatively designated 1277TATC; see 272800.0054. |
|
Gene |
HEXA |
Chromosomal Location |
15q23-q24 |
Allelic Variant 2 |
606869.0050; TAY-SACHS DISEASE |
Identified Mutation |
TRP392TER; Approximately 20% of Ashkenazi carriers harbor a splice-junction defect (272800.0002), while about 78% have a 4-bp insertion (272800.0001). However, the Ashkenazi patient used in the original description of the 4-bp insertion carried this lesion in only 1 allele and was negative for the splice junction mutation. Shore et al. (1992) cloned the insertion negative allele and by sequence analysis of the exons found a point mutation in exon 11 that resulted in substitution of trp392 with a premature termination codon. They found that 9 Ashkenazi Jewish carriers who had tested negative for the major and minor mutations as well as for a lesion causing an adult form of Tay-Sachs disease did not carry the trp392-to-ter mutation, suggesting that the mutation may be recent and/or rare. |
Remarks |
Pericardium fibro cult; Jewish; similarly aff sib; def hexosaminidase A activ; electrophoresis shows absence of A band; no detectable alpha chain synthesis; no detectable alpha chain mRNA; donor subject is a compound heterozygote: one allele has a 4-bp insertion in exon 11 of the HEXA gene [4 bp ins] that introduces a premature termination signal in exon 11 resulting in deficiency of mRNA and a second allele has a point mutation in exon 11 of the HEXA gene resulting in a substitution of a termination signal for tryptophan at codon 392 [Trp392Ter (W392X)]. |
Espejo-Mojica AJ, Rodríguez-López A, Li R, Zheng W, Alméciga-Díaz CJ, Dulcey-Sepúlveda C, Combariza G, Barrera LA, Human recombinant lysosomal ß-Hexosaminidases produced in Pichia pastoris efficiently reduced lipid accumulation in Tay-Sachs fibroblasts American journal of medical genetics Part C, Seminars in medical genetics: 2020 |
PubMed ID: 33111489 |
|
Mylinh Vu, Rong Li, Amanda Baskfield, Billy Lu, Atena Farkhondeh, Kirill Gorshkov, Omid Motabar, Jeanette Beers, Guokai Chen, Jizhong Zou, Angela J. Espejo-Mojica, Alexander Rodríguez-López, Carlos J. Alméciga-Díaz, Luis A. Barrera, Xuntian Jiang, Daniel S. Ory, Juan J. Marugan and Wei Zheng, Neural stem cells for disease modeling and evaluation of therapeutics for Tay-Sachs disease Orphanet Journal of Rare Diseases13:152 2018 |
PubMed ID: 30220252 |
|
Triggs-Raine BL, Feigenbaum AS, Natowicz M, Skomorowski MA, Schuster SM, Clarke JT, Mahuran DJ, Kolodny EH, Gravel RA, Screening for carriers of Tay-Sachs disease among Ashkenazi Jews. A comparison of DNA-based and enzyme-based tests. N Engl J Med323:6-12 1990 |
PubMed ID: 2355960 |
|
Paw BH, Kaback MM, Neufeld EF, Molecular basis of adult-onset and chronic GM2 gangliosidoses in patients of Ashkenazi Jewish origin: substitution of serine for glycine at position 269 of the alpha-subunit of beta-hexosaminidase [published erratum appears in Proc Natl Acad Sci U S A 1989 Jul;86(14):5625] Proc Natl Acad Sci U S A86:2413-7 1989 |
PubMed ID: 2522660 |
|
Arpaia E, Dumbrille-Ross A, Maler T, Neote K, Tropak M, Troxel C, Stirling JL, Pitts JS, Bapat B, Lamhonwah AM, et al, Identification of an altered splice site in Ashkenazi Tay-Sachs disease. Nature333:85-6 1988 |
PubMed ID: 3362213 |
|
Myerowitz R, Splice junction mutation in some Ashkenazi Jews with Tay-Sachs disease: evidence against a single defect within this ethnic group. Proc Natl Acad Sci U S A85:3955-9 1988 |
PubMed ID: 3375249 |
|
Myerowitz R, Costigan FC, The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase. J Biol Chem263:18587-9 1988 |
PubMed ID: 2848800 |
|
Ohno, Molecular genetics of B-N-acetyl-hexosaminidase alpha subunit mutations (from Lipid Storage Disorders, Plenum Publishing Corp) "Lipid Storage Disorders"1988, pp215:18587-9 1988 |
PubMed ID: 2848800 |
|
Ohno K, Suzuki K, A splicing defect due to an exon-intron junctional mutation results in abnormal beta-hexosaminidase alpha chain mRNAs in Ashkenazi Jewish patients with Tay-Sachs disease. Biochem Biophys Res Commun153:463-9 1988 |
PubMed ID: 2837213 |
|
Myerowitz R, Hogikyan ND, Different mutations in Ashkenazi Jewish and non-Jewish French Canadians with Tay-Sachs disease. Science232:1646-8 1986 |
PubMed ID: 3754980 |
|
Myerowitz R, Piekarz R, Neufeld EF, Shows TB, Suzuki K, Human beta-hexosaminidase alpha chain: coding sequence and homology with the beta chain. Proc Natl Acad Sci U S A82:7830-4 1985 |
PubMed ID: 2933746 |
|
Myerowitz R, Proia RL, cDNA clone for the alpha-chain of human beta-hexosaminidase: deficiency of alpha-chain mRNA in Ashkenazi Tay-Sachs fibroblasts. Proc Natl Acad Sci U S A81:5394-8 1984 |
PubMed ID: 6236461 |
|
Proia RL, Neufeld EF, Synthesis of beta-hexosaminidase in cell-free translation and in intact fibroblasts: an insoluble precursor alpha chain in a rare form of Tay- Sachs disease. Proc Natl Acad Sci U S A79:6360-4 1982 |
PubMed ID: 6959123 |
|
Frisch A, Neufeld EF, Limited proteolysis of the beta-hexosaminidase precursor in a cell-free system. J Biol Chem256:8242-6 1981 |
PubMed ID: 6455422 |
|
Hasilik A, Neufeld EF, Biosynthesis of lysosomal enzymes in fibroblasts. Phosphorylation of mannose residues. J Biol Chem255:4946-50 1980 |
PubMed ID: 6989822 |
|
Hasilik A, Neufeld EF, Biosynthesis of lysosomal enzymes in fibroblasts. Synthesis as precursors of higher molecular weight. J Biol Chem255:4937-45 1980 |
PubMed ID: 6989821 |
dbSNP |
dbSNP ID: 10342 |
Gene Cards |
HEXA |
Gene Ontology |
GO:0004563 beta-N-acetylhexosaminidase activity |
|
GO:0005764 lysosome |
|
GO:0005975 carbohydrate metabolism |
|
GO:0006687 glycosphingolipid metabolism |
|
GO:0016798 hydrolase activity, acting on glycosyl bonds |
NCBI Gene |
Gene ID:3073 |
NCBI GTR |
272800 TAY-SACHS DISEASE; TSD |
|
606869 HEXOSAMINIDASE A; HEXA |
OMIM |
272800 TAY-SACHS DISEASE; TSD |
|
606869 HEXOSAMINIDASE A; HEXA |
Omim Description |
B VARIANT GM2 GANGLIOSIDOSIS |
|
GM2-GANGLIOSIDOSIS, ADULT CHRONIC TYPE, INCLUDED |
|
GM2-GANGLIOSIDOSIS, TYPE I |
|
HEXA DEFICIENCYHEXOSAMINIDASE A, INCLUDED; HEXA, INCLUDED |
|
HEXOSAMINIDASE A DEFICIENCY |
|
HEXOSAMINIDASE A DEFICIENCY, ADULT TYPE, INCLUDED |
|
TAY-SACHS DISEASE, JUVENILE, INCLUDED |
|
TAY-SACHS DISEASE, PSEUDO-AB VARIANT, INCLUDED |
|
TAY-SACHS DISEASE, VARIANT B1, INCLUDED |
|
TAY-SACHS DISEASE; TSD |
Passage Frozen |
8 |
Split Ratio |
1:4 |
Temperature |
37 C |
Percent CO2 |
5% |
Percent O2 |
AMBIENT |
Medium |
Eagle's Minimum Essential Medium with Earle's salts and non-essential amino acids with 2mM L-glutamine or equivalent |
Serum |
15% fetal bovine serum Not inactivated |
Supplement |
- |
|
|